TREGTHERAPEUTICS

The T lymphocyte is a key component in the adaptive immune system, and a subset of T cells, the T regulatory cell (Treg), plays an instrumental role in the control and regulation of the immune response. Named in recognition of the vital functions this cell executes, TregTherapeutics Inc. is focused on development and clinical application of this elegant approach to the treatment and curative resolution of a wide range of diseases. The corporation is a North Carolina-based company whose proprietary technology is based upon an exclusive license granted by East Carolina University. TILAC is a transformative platform that harnesses the power of Tregs to dramatically alter patient outcomes in response to immunopathogenesis... TregTherapeutics Inc. is advancing a universal tolerance induction platform for autoimmune disease called "TILAC™" which stands for "Tolerance Induction by Linked Adjuvant/Cytokine conjugant. In addition, many other immune-associated inflammatory conditions, can be..

Also known as: TregTherapeutics, Inc